Successful fenofibrate therapy for severe and persistent hypertriglyceridemia in a boy with cirrhosis and glycerol‐3‐phosphate dehydrogenase 1 deficiency
Lorenza Matarazzo,
Valentina Ragnoni,
Cristina Malaventura,
Alberta Leon,
Davide Colavito,
Giovanni Battista Vigna,
Giovanni Lanza,
Aurelio Sonzogni,
Giuseppe Maggiore
Affiliations
Lorenza Matarazzo
Department of Medicine, Surgery, and Health Sciences University of Trieste Trieste Italy
Valentina Ragnoni
Section of Pediatrics, Department of Medical Sciences University of Ferrara Ferrara Italy
Cristina Malaventura
Section of Pediatrics, Department of Medical Sciences University of Ferrara Ferrara Italy
Alberta Leon
Research & Innovation Srl (R&I Genetics) Padova Italy
Davide Colavito
Research & Innovation Srl (R&I Genetics) Padova Italy
Giovanni Battista Vigna
Medical Department University of Ferrara Ferrara Italy
Giovanni Lanza
Department of Medical Sciences, Pathology Unit University of Ferrara Ferrara Italy
Aurelio Sonzogni
Department of Pathology ASST Papa Giovanni XXIII Bergamo Italy
Giuseppe Maggiore
Section of Pediatrics, Department of Medical Sciences University of Ferrara Ferrara Italy
Abstract Glycerol‐3‐phosphate dehydrogenase 1 deficiency is a rare autosomal recessive disorder caused by mutations in the GPD1 gene (GPD1; OMIM*138420). Very few cases are reported in literature. It usually manifests in early infancy with transient hypertriglyceridemia, hepatomegaly, steatosis, and fibrosis. We report the case of a 16‐year‐old boy followed since the age of 1 year for hepatomegaly, elevated liver enzymes, and persistent hypertriglyceridemia. Abdominal ultrasound showed diffuse liver echogenicity and liver biopsy disclosed cirrhosis with micro and macrovesicular steatosis. Next‐generation sequencing for metabolic and genetic liver diseases was conducted with the identification of the homozygous mutation c.895G>A in GPD1 gene resulting in the aminocidic substitution p.G299R. Considering the persistent and progressive increase of plasma triglycerides, fenofibrate treatment was started at 15 years of age allowing triglyceride level reduction in the following 1‐year follow‐up.